Chukwuemeka (Emeka) Venatius Ikpeazu, M.D., Ph.D., M.B.A., F.A.C.P. Work Phone #: Work Fax #: Citizenship: U.S.A.

Transcription

1 DATE: September 17, 2014 I. PERSONAL Chukwuemeka (Emeka) Venatius Ikpeazu, M.D., Ph.D., M.B.A., F.A.C.P. Work Phone #: Work Fax #: Citizenship: U.S.A. Practice Address: University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center Plantation 8100 SW 10 th Street Plantation, FL Higher Education University of Nebraska ( ), Lincoln/Omaha, Nebraska B.S. Degree in Biology in August, 1982 Meharry Medical College ( ), Nashville, Tennessee Ph.D. Degree in Biomedical Sciences. May, 1988 Meharry Medical College ( ), Nashville, Tennessee M.D. Degree. May, 1992 (With Honors) Mayo Graduate School of Medicine, Rochester, Minnesota. Residency Program: (Internal Medicine) June 1992 to June 1994 Meharry Medical College, Nashville, Tennessee Residency Program: (Internal Medicine) July 1994 to June 1996 East Tennessee State University School of Medicine, Johnson City, Tennessee Fellowship Program: (Medical Oncology) July 1996 to June 1998 Vanderbilt University Medical Center, Nashville, Tennessee Fellowship Program: Hematology/Bone Marrow Transplantation July1998 to June 2000 University of Massachusetts, Isenberg School of Management, Amherst, Massachusetts (6/2009-5/2011). M.B.A. degree: Focused on Healthcare Management Licensure and Certifications 1

2 Medical Licensure Florida Board of Medicine, #ME Tennessee Board of Medical Practice, #MD Certifications Diplomat, National Board of Medical Examiner of U.S.A., 1993, Certificate # Diplomat, American Board of Internal Medicine, ( ). Recertified 05/07 ( ). Certificate # Diplomat, American Board of Internal Medicine, Medical Oncology, ( ), Certificate # Recertified 05/2010 ( ). BLS Certified (7/2009 9/2013). ACLS Certified (Jan 2013 January 2015) Academic Appointments Current Academic Appointment Associate Professor (Jan Present) Division of Hematology/Oncology Department of Internal Medicine University of Miami-Miller School of Medicine 1475 NW 12 th Avenue, Suite 3400 Miami, FL Former Academic Appointments Assistant Professor of Medicine, Aug Nov Associate Professor of Medicine, Nov Dec Acting Chief, Division of Hematology/Oncology, Aug 2000 July 2003 Co-Director, Minority-Based Community Clinical Oncology Program Principal Investigator, Oncology Clinical Trials. Course Director, Annual Internal Medicine Board Review Course, Meharry Medical College 1008 D.B. Todd Blvd Nashville, TN Adjunct Faculty member, Sept Dec Division of Hematology-Oncology Dept. of Internal Medicine Vanderbilt University Medical Center st Avenue South Nashville, TN

3 Hospital Appointments Current Hospital Appointments University of Miami Hospitals and Clinics (Dec Present) 1475 NW 12 th Avenue Miami, FL Dept of Medicine, Hematology & Oncology (Jan Present) Jackson Memorial Hospital 1611 NW 12 th Avenue Miami, FL Division of Medical Oncology (Dec Present) Boca Raton Regional Hospital 800 Meadows Road Boca Raton, FL Department of Internal Medicine West Boca Medical Center State Road 7 Boca Raton, FL Former Hospital Appointment Chief, Oncology and Hematology, Aug Dec Chairman, Tumor Board (Aug 2000 Dec. 2007) Co-Chairman, Cancer Committee (Aug 2006 Feb 2006) Chairman, Cancer Committee (Feb 2006 Dec 2007) Principal Investigator, Oncology Clinical Trials Attending Physician, Medical Services Metro Nashville General Hospital 1818 Albion Street Nashville, TN Current Miscellaneous Activities Professional Society Membership Member, The American Society for Clinical Oncology Fellow, American College of Physicians-American Society for Internal Medicine Member, Alpha Omega Alpha honors Medical Society Member, American College of Physician Executive Teaching Responsibilities Selected lectures in Thoracic Oncology for Hematology/Oncology Fellows. 3

4 Attending, Thoracic and Head & Neck Oncology Fellows Clinic at Jackson Memorial Hospital Clinical Specialty Thoracic, Head & Neck Oncology, Sarcomas, Melanomas, Unknown Primary as well as Thyroid Carcinomas. Speaking Activities I served or currently serving as a speaker for Archimedes Pharma, Sanofi- Aventis, Lilly, Merck, Response Genetics, EUSA Pharma, and Precision Therapeutics in the areas of Lung cancer, supportive oncology, and personalized medicine. I have served in the Advisory Boards of Amgem, Norvatis, Biodesix, Inc., etc. Peer Reviewer for CME Hematology/Oncology Medical Review Grants Written National Cancer Institute Title: MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM Approved: 06/01/04 to 05/31/07 Renewed: 09/2007 to 09/2012 Total costs: $2,839,794 Role: Co-Principal Investigator CLINICAL TRIAL POTFOLIO Site Principal Investigator for ECOG 1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer. Site Principal Investigator for ImClone Protocol CP : A Randomized Phase II Open-Label Study of IMC-A12, as a Single agent or in Combination with Cetuximab, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head & Neck and Disease Progression on Prior Platinum-Based Chemotherapy. Publications and Manuscripts 1. Ikpeazu, E.V., Valenzuela, M.S. : A Unique Deletion in pbr322 DNA Caused by Insertion of Poly (da). Poly (dt). Plasmid 21, (1989). 2. Hardy, R.E., Ikpeazu, E.V.: Bone Marrow Transplantation: A Review. J. Natl. Med. Assoc. 81(5): , May,

5 3. Valenzuela, M.S., Ikpeazu, E.V., Siddiqui, K.A.I. : E. coli Growth Inhibition by a High Copy Number Derivative of Plasmid pbr322. Biochem. Biophys. Res. Comm. 219, (1996). 4. Ikpeazu, E.V. and Kaplon, M.K.: Cryptococcal Meningitis occurring at 19 months after Cladribine therapy for Hairy Cell Leukemia. Eur. J. Haematol Oct. 61(4): Ikpeazu, E.V.; Davidson, M.; Halteman, D; Goodman, S.; Browning, P.; and Brandt, S.: Donor Origin of Circulating Endothelial Cell Progenitors after Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation 6: (2000). 6. Coates L, Ikpeazu EV, Chen Y, Valenzuela MS. Inhibition of DNA replication by berenil in plasmids containing Poly(dA)poly(T) sequences. Plasmid 2002 Mar; 47(2): Gilbert J, Dang T, Cmelak A, Shyr Y, Netterville J, Burkey B, Chung CH, Ikpeazu E and Murphy BA: Single Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN). Clinical Medicine: Oncology 2007: Ikpeazu, Chukwuemeka. Biomarker Analysis In The Management Of Advanced Non-Small Cell Lung Cancer. Manuscript in preparation. ABSTRACTS 1. Ikpeazu, E.V., Valenzuela, M.S.: Construction of Recombinant Plasmids Containing Berenil-Target Sequences. October, (Abstract #95). NIH Centennial MBRS Symposium. Washington, D.C. 2. Ikpeazu, E.V., Valenzuela, M.S.: Specific Deletions Caused By Insertion of POLY da-dt in pbr322 DNA. May, American Society for Biological Chemists/Federation of American Society for Experimental Biology (ASBC/FASEB) Meeting. Las Vegas, Nevada. 3. Kumar, P.P. and Ikpeazu, E.V.: Biochemical Response Following External Radiation Therapy in The Treatment of Localized Prostate Cancer. May 16-19, (Abstract #1295). Proceedings of The American Society For Clinical Oncology (ASCO) 34 th Annual Meeting, Los Angeles, Ca. 4. Ikpeazu, E.V., T. Ward, A.B. Karnad.: Problems With PSA-Based Screening For Prostate Cancer In Veterans. May 16-19,

6 (Abstract #1291). Proceedings of The American Society For Clinical Oncology (ASCO) 34 th Annual Meeting, Los Angeles, Ca. 5. Ikpeazu, E., Vangel, M., Schiller, J.H., Bonomi, P.D., Johnson, D.H.: Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum-Based Chemotherapy in Two Eastern Cooperative Group Trials: The Influence of Race. Poster and Abstract # Proceedings of The American Society For Clinical Oncology (ASCO) 39 th Annual Meeting, 2003, Chicago, Il. 6. Ikpeazu, CV; Murphy, BA; Kish, B; Cmelak, A; Shyr, Yu; Netterville, J; Burkey, B; Chung, W; Yarbrough, W.: Phase II Trial of Irinotecan Plus Cisplatin in Patients with Recurrent or Metastatic Squamous Carcinoma of the Head and Neck (RMHNC). Poster and Abstract #438. PASCO 40 th Annual Meeting, June 2004, New Orleans, LA. 7. Wujcik, D; Ikpeazu, C; Chinratanalab, W; Wolff, SN; Kinnard, C; McCullough, N; Mason, HRC; Stain, SC.: Strategies to Improve Minority Patient Accrual to Cancer Clinical Trials. Poster and Abstract #2294. PASCO 40 th Annual Meeting, June 2004, New Orleans, LA. 8. Kunal Saigal, Sean Warsch, Amar Mandalia, Michael Samuels, Khaled A. Tolba, Chukwuemeka Ikpeazu, Deukwoo Kwon, Edgardo S. Santos; University of Miami, Miami, FL; University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL; University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL: Concurrent chemoradiotherapy using carboplatin/cetuximab regimen in patients with locally advanced head and neck squamous cell carcinoma (LA- HNSCC) not eligible for high-dose cisplatin (HD-DDP). Abstract # PASCO 52 nd Annual Meeting, May 2012, Chicago, IL. 6